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Table 1 Antiproliferative activity (IC50) values of monensin (MON) and its analogues.
Compound IC50
MON 612.6 ± 184.4 &
MONNa 106.2 ± 37.0 ***
NS-003 487.6 ± 161.2
NS-008 604.9 ± 149.6
NS-001 291.7 ± 68.8 **
NS-005 189.8 ± 79.3 **
NS-004 622.7 ± 203.8
NS-012 168.7 ± 82.2 **
NS-023 100.0 ± 92.0 ***
NS-016 994.9 ± 330.3
NS-022 257.3 ± 135.6 *
NS-017 808.3 ± 103.4
NS-018 139.0 ± 105.4 **
NS-026 91.5 ± 54.4 ***
NS-024 424.0 ± 288.6
NS-025 337.0 ± 217.1
IC50 value is defined as the concentration of the compound which induces 50% growth inhibition. Values are given as mean ± SD (n=4 each).
& The value is an average from two independent experiments (n = 4 each)
*p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001.
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ABSTRACT
Characterized by extensive vascularization with poor prognosis, glioblastoma multiforme (GBM) is
the most aggressive form of brain tumor in adults.1 With limited treatment options ranging from
surgery, chemotherapy, and radiotherapy, GBM’s survival rate is remarkably poor with only 2% of
patients living three years or longer post diagnosis.2 One of the main problems contributing to
limited effective treatment options and poor overall survival is the lack of the models of the disease
which could reliably recapitulate tumor heterogeneity. Organoids, are 3D, self-organized structures
which mimic the endogenous tumor architecture, microenvironment, and cellular interactions,
which makes them an improved model for anti-cancer drug discovery.3 Monensin (MON) is a
polyether ionophore antibiotic with antiparasitic, antibacterial, antifungal, antiviral, and anticancer
properties.1 It has been approved by FDA for the use in veterinary medicine as an anti- parasitic
agent, but despite its promising activity it has not yet been approved as a therapy for humans. In
this work, we investigated the effect of MON and its analogues on GBM organoids. We identified
seven analogues characterized by lower IC50 values towards those organoids than parent
molecule. All of those compounds induced significant DNA fragmentation after 72 h of treatment.
Further studies revealed that MON and its most potent analogue NS-001 induced PARP cleavage
and its degradation, and increased the expression of the autophagy marker LC3II. Additional
studies are warranted in order to investigate therapeutic potential of those promising molecules as
anti-GBM agents.
CONCLUSIONS
• Seven novel MON derivatives showed higher activity (characterized by lower IC50 
Values) towards GBM organoids than parent molecule.
• MON and NS001 analogue induced PARP cleavage and degradation after 24 and 48 
hrs. 
• MON and NS001 analogue induced upregulation of LC3B after 24 and 48 hrs.
• All seven analogues of MON induced significant DNA fragmentation as determined by 
P1 staining after 72 hours of treatment. (data not shown)
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Days
Fig 1. General procedure of organoid generation and culturing 
ORGANOID CULTURE AND DRUG TREATMENT
Scheme 1. Synthesis of monensin and its analogues 
Figure 3,4. Organoids day 4. Figure 5. (top right) Organoids day 6 cut 
Fig 3. Uncut organoid day 4                                     Fig 4. Cut organoid day 6  
RESULTS
Mon 48 hrs., and NS-001 48 hrs. induce PARP cleavage and degradation in U118 MG organoids.
PARP
GAPDH
Mon 24 hrs., 48 hrs., NS-001 24 hrs., and 48 hrs. increase LC3BII synthesis in U118 MG organoids.
LC3
GAPDH 
NS-001 48 hrs. induces an increase of 𝛾H2AX in U118 MG organoids.
𝛾H2AX
GAPDH
Fig 2. Drug treatment 
setup
Fig 7. Decreased PARP bands in MON 
48 & NS001 48 is a marker for 
apoptosis in these groups.
GAPDH was employed as a loading 
control.
Fig 8. Increased expression of LC3BII 
in compound tested groups is a 
marker for autophagy.
Fig 9. Increased expression of 𝛾H2AX
in NS001 48 hrs. is a sign of DNA 







MON 612.6 ± 184.4 
MONNa 106.2 ± 37.0 ***
NS-003 487.6 ± 161.2
NS-008 604.9 ± 149.6
NS-001 291.7 ± 68.8 **
NS-005 189.8 ± 79.3 **
NS-004 622.7 ± 203.8
NS-012 168.7 ± 82.2 **
NS-023 100.0 ± 92.0 ***
NS-016 994.9 ± 330.3
NS-022 257.3 ± 135.6 *
NS-017 808.3 ± 103.4
NS-018 139.0 ± 105.4 **
NS-026 91.5 ± 54.4 ***
NS-024 424.0 ± 288.6
NS-025 337.0 ± 217.1
Table 1. Antiproliferative activity (IC50) values of monensin (MON) and its analogues. 
IC50 value is defined as the concentration of the compound
which induces 50% growth inhibition. Values are given as
mean ± SD (n=4 each).
& The value is an average from two independent
experiments (n=4 each)
*p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001.
Source: DOI: 10.1111/cbdd.13581
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GAPDH was employed as a loading 
control.
GAPDH was employed as a loading 
control.
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